BioSpace News Archive

DataLink Software (DataLink) the leader in value-based healthcare technology solutions has enhanced its point-of-care solution and connectivity

Polarean Imaging plc (AIM:POLX), the clinical stage medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that it will receive a third tranche of US$1 million as part of its US$3 million Small Business Innovation Research (“SBIR”) grant.

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology (ASM) Microbe 2019 meeting to be held in San Francisco, CA, USA, June 20-24, 2019

Essity is divesting its 50% stake in the partly owned company SCA Yildiz in Turkey to the other part owner Yildiz.

The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.

Interestingly, between 2017 and 2018, there was a significant slowdown in contactless migration, driven by stagnation in the key contactless market, China.

Shipments for Follow-on Order Under Existing Supply Agreement Will Commence This Quarter

The Workers’ Compensation Benchmarking Study’s annual survey is underway.

Nordic Nanovector ASA announces that following a safety review of the first patients in the ongoing Archer-1 trial investigating Betalutin® in combination with rituximab in second-line follicular lymphoma, the Betalutin® dose has been escalated to 15 MBq/kg for the next cohort of patients.

iX Biopharma Ltd announced that following the completion of its Phase 2 clinical study on Wafermine, a sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain, the U.S. Food and Drug Administration has scheduled the End-of-Phase 2 meeting with the Company in the third quarter of 2019.